Zimmer Biomet (ZBH) Competitors

Penumbra (NYSE:PEN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Is PEN or ZBH more profitable?

Penumbra has a net margin of 11.54% compared to Zimmer Biomet's net margin of 10.51%. Zimmer Biomet's return on equity of 12.76% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.54%	11.55%	8.76%
Zimmer Biomet	10.51%	12.76%	7.21%

Do institutionals and insiders hold more shares of PEN or ZBH?

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.0% of Penumbra shares are owned by company insiders. Comparatively, 0.7% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media favor PEN or ZBH?

In the previous week, Zimmer Biomet had 29 more articles in the media than Penumbra. MarketBeat recorded 43 mentions for Zimmer Biomet and 14 mentions for Penumbra. Penumbra's average media sentiment score of 1.22 beat Zimmer Biomet's score of 0.98 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	22 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, PEN or ZBH?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.19B	8.14	$14.01M	$3.76	66.32
Zimmer Biomet	$7.83B	2.58	$903.70M	$4.11	24.79

Do analysts rate PEN or ZBH?

Penumbra presently has a consensus target price of $300.47, indicating a potential upside of 20.49%. Zimmer Biomet has a consensus target price of $111.44, indicating a potential upside of 9.38%. Given Penumbra's stronger consensus rating and higher possible upside, equities analysts clearly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35

Which has more risk and volatility, PEN or ZBH?

Penumbra has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Summary

Penumbra beats Zimmer Biomet on 10 of the 17 factors compared between the two stocks.